DynaGen regulatory update

DYGN received notice of allowance for a U.S. patent covering the use of ImmuDyn, a lipid-based immunomodulator, to treat HIV. DYGN's Apex Pharmaceuticals Inc. subsidiary is developing ImmuDyn initiall...